Keros Therapeutics Inc (KROS): Narxning sotuvga nisbati

Keros Pharma (KROS) kompaniyasining korporativ logotipi

Ijobiy imij va Keros Therapeutics (KROS) loyihalari portfeliga bo'lgan ishonch ishonchli o'sish trayektoriyasini ta'minlamoqda. Keros Therapeutics orfan bozorini nishonga olgan suyak va gematologik patologiyalar uchun terapiya vositalarini ishlab chiqadi. Moliyaviy model innovatsion ishlanmalar uchun investitsiyalar va sheriklik to'lovlariga tayanadi. Kapitalizatsiyaning daromadga nisbati aktivning baholash dinamikasini aks ettiradi, bunda 4.90 joriy metrika darajasi sifatida xizmat qilib, bozor anomaliyalarini o'z vaqtida aniqlash imkonini beradi.

KROS: Keros Therapeutics P/S multiplikatori 04.07.2022 - 17.11.2026

kerostx.com (KROS) kompaniyasi koʻrsatkichlari kesimi va tahlili

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- birja kapitallashuvi ma'lumotlari:
Kompaniyaning umumiy tahlili:KROS Keros Therapeutics Inc
Keros Therapeutics tayyor mahsulotlari

Bozor Keros Therapeutics (KROS) kompaniyasini uning diversifikatsiyalashgan biofarmatsevtika portfelining istiqbollari prizmasidan baholaydi, bunda klinik sinovlarning muvaffaqiyati kelajakdagi kapitalizatsiyani belgilaydi. Joriy P/S koeffitsiyentini tahlil qilish orqali investor bozor qiymati va tushumlar o'rtasidagi bog'liqlikni o'rganishi mumkin, bu esa aktivlar uchun haddan tashqari to'lovni aniqlash va biznesning uzoq muddatli moliyaviy barqarorligini ta'minlash uchun ilmiy ishlanmalarni monetizatsiya qilish samaradorligini baholash imkonini beradi.

Keros Therapeutics raqobatchilari

VRTX (Vertex Pharmaceuticals Incorporated) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Alnylam ALNY|INSM (Insmed Inc) - Narxning sotuvga nisbati|United Therapeutics - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati BMRN (BioMarin Pharmaceutical)|BBIO: P/S multiplikatori|BGM Group Corp - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Cogent Bio|XERS: Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati arcturusrx.com (ARCT)|Kapitalizatsiyaning daromadga nisbati Eton Pharmaceuticals ETON|P/S multiplikatori KMDA (kamada.com)|P/S multiplikatori Fulcrum Therapeutics, Inc. FULC|Abeona Therapeutics - P/S multiplikatori|mereobiopharma.com (MREO) - Kapitalizatsiyaning daromadga nisbati|Protalix BioTherapeutics Inc. (PLX) - Narxning daromadga nisbati|PLRX (Pliant Therapeutics Inc) - Narxning daromadga nisbati|Narxning daromadga nisbati Applied Therapeutics, Inc.|Rein Therapeutics Inc. (RNTX) - Narx/daromad koeffitsiyenti|Kapitalizatsiyaning daromadga nisbati GELS (Gelteq Limited)|P/S multiplikatori Aytu Therapeutics (AYTU)|Narxning daromadga nisbati Chemomab Therapeutics Ltd. CMMB|Bozor kapitallashuvining daromadga nisbati SRXH|Polyrizon Limited - P/S multiplikatori|AEZS (zentaris.com) - Kapitalizatsiya va daromad nisbati|CYTH (Cyclo Therapeutics, Inc.) - Kapitalizatsiyaning daromadga nisbati|Sotuvga nisbatan narx Inozyme Pharma, Inc. (INZY)|RPHM (Reneo Pharmaceuticals) - P/S multiplikatori|COSCIENS Biopharma (CSCI) - Narx/daromad koeffitsiyenti